Market capitalization | $648.40m |
Enterprise Value | $470.10m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.55 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-189.21m |
Free cash flow (TTM) Free cash flow | $-152.02m |
Cash position | $238.43m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.60 -0.60 |
76%
76%
|
|
EBITDA | -58 -58 |
52%
52%
|
EBIT (operating result) EBIT | -58 -58 |
44%
44%
|
Net profit | -57 -57 |
44%
44%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Jay Backstrom |
Employees | 150 |
Founded | 2012 |
Website | www.scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.